Sign in

TELO on Nasdaq

Telomir Pharmaceuticals, Inc.

Telomir Pharmaceuticals, Inc. is an American pharmaceutical preparations company based in Tampa.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with another stock.

  • TickerTELO on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersMiami, Florida1
  • Incorporated inFL2
  • Business address100 Se 2Nd St, Suite 2000 #1009, Miami, Fl 331312
  • Filer category, Emerging growth company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Net income345-$10.4M in 2025+1119% since 2022
-$20.0M-$15.0M-$10.0M-$5.0M02022: -$854.1K-$854.1K20222023: -$13.1M-$13.1M2023+1430%2024: -$16.5M-$16.5M2024+26%2025: -$10.4M-$10.4M2025−37%

Every line of the income statement as filed: the last 2 fiscal years, latest first.5

Period ending2025-12-312024-12-31
General and administrative expenses$8.1M$9.6M
Related party travel costs$370.5K
Research and development expenses$2.4M$2.2M
Total operating costs$10.5M$12.2M
Interest income$125.6K$48.0K
Interest expense-$4.3M
Net loss-$10.4M-$16.5M
Basic loss per share-$0.33-$0.56
Diluted loss per share-$0.33-$0.56
Basic weighted average common stock shares outstanding31.7M shares29.5M shares
Diluted weighted average common stock shares outstanding31.7M shares29.5M shares

Compare Telomir Pharmaceuticals, Inc. with another company

Corporate structure

Telomir Pharmaceuticals, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Telomir Pharmaceuticals, Inc.

  • John Paul DeJoria Filed SCHEDULE 13G/A on Telomir Pharmaceuticals, Inc., latest Aug 14, 2026 (3 filings since Sep 18, 2025)
  • Telomir Pharmaceuticals, Inc. Miami, Florida

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Telomir Pharmaceuticals, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Properties, in its own words

Our former corporate headquarters was located in Baltimore, Maryland, which included a lease for office space. This lease began in November 2022 and expired in April 2024. The lease was not renewed. We moved all corporate related activities in April 2024 to a shared office space in Tampa, Florida, see Note 5. In September 2024, we decided to no longer utilize the shared space and moved to a virtual office model. As of October 1, 2024, we have not had a physical office space.

Item 2 of the 10-K filed Mar 17, 2026.8

Leadership

Who has led Telomir Pharmaceuticals, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Erez Aminov2024–now

Chair

  1. Erez Aminov2024–now

Chief financial officer

  1. Nathen Fuentes2024
  2. Michelle Yanez2024
  3. Alan Weichselbaum2025–2026
  4. Andriy Mushak2026–now
2025
Board members and other officers (8)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • President, Chief Executive Officer and ChairmanChris Chapman named Apr 3, 202321
  • Treasurer, Chief Financial Officer and SecretaryJames McNulty named Apr 3, 202321
  • DirectorDavid Vorhoff named Apr 3, 202321
  • DirectorHugh McColl named Apr 3, 202321
  • DirectorJude Uzonwanne named Apr 3, 202321
  • DirectorTuck Talhia named Apr 3, 202321

Timeline

  1. Oct 6, 20268-K Entered a material agreement; Unregistered sale of shares; Regulation FD disclosure22
  2. Sep 17, 20268-K Regulation FD disclosure23
  3. Sep 16, 20268-K Shareholder vote24
  4. Sep 14, 20268-K Regulation FD disclosure25
  5. Aug 10, 20268-K Regulation FD disclosure26
  6. Jun 15, 20268-K Regulation FD disclosure27
  7. Jun 8, 20268-K Executive or director change28
  8. May 20, 20268-K Regulation FD disclosure29
  9. Apr 30, 20268-K Other events30
  10. Apr 24, 20268-K Entered a material agreement; Completed an acquisition or sale; Unregistered sale of shares31
  11. Mar 31, 20268-K Other events32
  12. Mar 31, 20268-K Other events33
  13. Aug 15, 2024New chief executive Erez Aminov becomes CEO9

Calendar

Coming up

  1. Nov 9, 2026Reports results for the quarter ending Sep/202634

Drug trials and FDA: coming up

  1. May 2027Phase 1/2 trial readout expected Phase 1/2 trial of Zn-Telomir in Triple-Negative Breast Cancer (TNBC): primary completion expected May 2027 (ClinicalTrials.gov NCT07581314).35

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar

Filings

146 filings to the SEC since October 2021: 3 annual reports, 8 quarterly reports, 63 major events, 35 insider forms, 3 large holders, 1 private raises, 33 other. The latest 20:

  1. Oct 6, 20268-K EDGAR
  2. Sep 17, 20268-K EDGAR
  3. Sep 16, 20268-K EDGAR
  4. Sep 14, 20268-K EDGAR
  5. Aug 19, 2026DEFA14A EDGAR
  6. Aug 14, 2026SCHEDULE 13G/A EDGAR
  7. Aug 13, 202610-Q EDGAR
  8. Aug 10, 20268-K EDGAR
  9. Jul 28, 2026DEF 14A EDGAR
  10. Jul 27, 20264 EDGAR
  11. Jul 27, 20264 EDGAR
  12. Jul 27, 20264 EDGAR
  13. Jun 15, 20268-K EDGAR
  14. Jun 9, 20263 EDGAR
  15. Jun 8, 20268-K EDGAR
  16. May 22, 20264 EDGAR
  17. May 22, 20264 EDGAR
  18. May 22, 20264 EDGAR
  19. May 22, 20264 EDGAR
  20. May 20, 20268-K EDGAR

The 146 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

2 open-market trades by officers, directors and large owners since October 2021: 1 buys and 1 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Aug 19, 2024Aminov ErezCEO and ChairmanSale400$6.11$2.4KForm 4
Feb 13, 2024McNulty Brian Patrick10% ownerBuy138,000$7.00$966.0KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

  • John Paul DejoriaSCHEDULE 13G/A, 3 filings Sep 18, 2025 to Aug 14, 202636

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Erez Aminov,48$275.0K$4.9M37
2025Alan Weichselbaum,$37.0K$139.8K37
2025Michelle Yanez,$106.9K37
2024(Chairman and CEO)$106.1K$7.6M37
2024(Former CFOTreasurer, and Secretary)$74.5K$865.4K37
2024(Former Chairman and CEO)$154.1K$156.8K37

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Money received by year$1.0M 2023–2023
Money received by yearMoney received by year, 2023–2023: $1.0M in all. Private raises (Form D) $1.0M.$0$250K$500K$750K$1M2023 · Private raises (Form D): $1.0M2023
Figures by year
YearPrivate raises (Form D)Total
2023$1.0M$1.0M

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

  1. Mar 15, 2023Raised $1 million in a private offering of equity21 Form D: 10 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 33. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Vanguard Capital Management LLC1,613,639$2.1M0.0%+618,266
Geode Capital Management, LLC338,875$433.9K0.0%+89,789
BlackRock, Inc.280,472$359.0K0.0%−8,726
Vanguard Fiduciary Trust Co225,304$288.4K0.0%+89,763
Northern Trust Corp61,532$78.8K0.0%+19,688
State Street Corp58,600$75.0K0.0%No change
Bank of New York Mellon Corp51,454$65.9K0.0%No change
Captrust Financial Advisors51,194$65.5K0.0%New
Osaic Holdings, Inc.41,490$53.1K0.0%+5,695
World Investment Advisors37,037$48.1K0.0%No change
OneDigital Investment Advisors LLC23,000$29.4K0.0%No change
Qube Research & Technologies Ltd21,792$27.9K0.0%New
Praetorian Wealth Management, Inc.20,000$25.6K0.0%No change
Vestmark Advisory Solutions, Inc.13,600$17.4K0.0%+500
Citadel Advisors LLC13,266$17.0K0.0%New
Morton Capital Management LLC/CA12,658$16.2K0.0%No change
Two Sigma Securities, LLC12,616$16.1K0.0%New
Clearstead Advisors, LLC12,530$16.0K0.0%No change
NorthCrest Asset Manangement, LLC12,119$15.4K0.0%New
Kestra Private Wealth Services, LLC11,000$14.1K0.0%No change
Regions Financial Corp10,638$13.6K0.0%No change
UBS Group AG7,959$10.2K0.0%−1,254
Tower Research Capital LLC (TRC)7,920$10.1K0.0%New
Vanguard Global Advisers, LLC6,552$8.4K0.0%No change
Royal Bank Of Canada754$1.0K0.0%New

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Telomir Pharmaceuticals, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARTelomir Pharmaceuticals, Inc.1
  • CIK0001971532
  • Employer ID (EIN)85-33545478
  • Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; a shell company8
  • Incorporated inFlorida8
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address100 Se 2Nd St, Suite 2000 #1009, Miami, FL 331311
  • Phone786-396-67231
  • Shares outstanding68,774,956 as of Aug 12, 20267
  • Public float$18.1M as of Jun 30, 20258
  • AuditorSALBERG & COMPANY, P.A., Boca Raton, Florida PCAOB ID 106; it also attests to the company’s internal control over financial reporting8
  • On EDGAR sinceApr 3, 20231
  • Filings146 in all: 8-K (63), 3 (17), 4 (17), 10-Q (8), CORRESP (6), UPLOAD (5), 10-K (3), PRER14A (3)1
    All 27 form types

    S-1/A (3), DEFA14A (2), EFFECT (2), SCHEDULE 13G/A (2), 424B1 (1), 424B4 (1), 5 (1), 8-A12B (1), CERT (1), D (1), DEF 14A (1), DEFM14A (1), DRS (1), DRS/A (1), DRSLTR (1), PREM14A (1), S-1 (1), S-3 (1), SCHEDULE 13G (1)

  • Latest filingsAnnual report (10-K) Mar 17, 2026
    Quarterly report (10-Q) Aug 13, 2026
    Proxy statement (DEF 14A) Jul 28, 2026
    Latest 8-K (8-K) Oct 6, 2026

Securities registered for trading

ClassSymbolExchange
Common stock, no par valueTELONasdaq

From the cover page of the 10-K filed Mar 17, 2026 (Section 12(b) of the Exchange Act).8

Risk factors and legal proceedings

The risks Telomir Pharmaceuticals, Inc. names in Item 1A of its 10-K filed Mar 17, 2026: 64 risks under these headings, as written.8

  • Risks Related to Our Intellectual Property
  • We depend on rights to Telomir-1 that are or will be licensed to us. We do not own the intellectual property rights to Telomir-1 and any loss of our rights to it could prevent us from selling our product.
  • We may not be able to adequately protect our product candidates or our proprietary technology in the marketplace.
  • If third parties claim that our intellectual property, products, processes, or anything else used by us infringes upon their intellectual property, our operating profits could be adversely affected.
  • We have been granted a license to the right to develop Telomir-1 in the United States in human and pet application, but we have not been granted a license to the rights to patents covering Telomir-1 in foreign jurisdictions.
  • Risks Related to Our Operations and Financial Condition
  • We are an early development-stage company with no revenues.
  • Because we have a limited operating history, you may not be able to accurately evaluate our operations.
  • We will need to raise additional financing for the continuation of our operations.
  • Our operating results may fluctuate, which could have a negative impact on our ability to grow our client base, establish sustainable revenues and succeed overall.
  • As a result of these factors, we may not succeed in our business, and we could go out of business.
  • We have yet to achieve a profit and will not achieve a profit in the near future, if at all.
The other 54 risks
  • Certain of our executive officers are not employed by us on a full-time basis.
  • Conflicts of interest may arise between us and MIRALOGX.
  • Risks Relating to Our Business and Our Industry
  • Our future success will largely depend on the success of Telomir-1 and any future product candidates, which development will require significant capital resources and years of clinical development effort.
  • We are dependent on our current and future product candidates, some of which may not receive regulatory approval or be successfully commercialized.
  • Results of pre-clinical studies and earlier clinical trials are not necessarily predictive indicators of future results.
  • We have limited marketing experience, and we do not anticipate at this time establishing a sales force or distribution and reimbursement capabilities, and we may not be able to successfully commercialize any of our product candidates if they are approved in the future.
  • We will need to further increase the size and complexity of our organization in the future, and we may experience difficulties in managing our growth and executing our growth strategy.
  • We expect to face intense competition, often from companies with greater resources and experience than we have.
  • Business interruptions could delay us in the process of developing our product candidates and could disrupt our product sales.
  • We have significant and increasing liquidity needs and may require additional funding.
  • Operating results may vary significantly in future periods.
  • We depend upon our key personnel and our ability to attract and retain employees.
  • Our proprietary information, or that of our customers, suppliers, and business partners, may be lost or we may suffer security breaches.
  • Failure of our information technology systems, including cybersecurity attacks or other data security incidents, could significantly disrupt the operation of our business.
  • Security breaches, loss of data and other disruptions could compromise sensitive information related to our business, prevent us from accessing critical information or expose us to liability, which could adversely affect our business and our reputation.
  • Geopolitical events and global economic conditions, such as the Israel-Hamas war may impact the third parties that we engage to supply materials or manufacture any products for our preclinical tests and clinical trials, which increases the risk of potential delay of development efforts, as applicable.
  • Risks Related to Development and Regulatory Approval of Our Product Candidates
  • Clinical trials for our product candidates are expensive, time-consuming, uncertain, and susceptible to change, delay or termination. The results of clinical trials are open to differing interpretations.
  • Any failure by us to comply with existing regulations could harm our reputation and operating results.
  • The regulatory approval processes with the FDA are lengthy and inherently unpredictable.
  • There is a high rate of failure for drug candidates proceeding through clinical trials.
  • If we are found in violation of federal or state “fraud and abuse” laws, we may be required to pay a penalty and/or be suspended from participation in federal or state health care programs, which may adversely affect our business, financial condition, and results of operations.
  • Serious adverse events or other safety risks could require us to abandon development and preclude, delay or limit approval of our product candidates, limit the scope of any approved label or market acceptance, or cause the recall or loss of marketing approval of products that are already marketed.
  • Risks Related to Our Reliance Upon Third Parties
  • We rely on, and expect to continue to rely on, third parties to conduct clinical trials for our product candidates. If these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, we may not be able to obtain marketing approval for or commercialize our product candidates, and our business could be substantially harmed.
  • We currently rely on a third party for the manufacture of Telomir-1 for clinical development and expect to continue to rely on third parties for the foreseeable future. This reliance on third parties increases the risk that supplies of our product may not be manufactured in accordance with specifications or that we will not have sufficient quantities of Telomir-1 or such quantities at an acceptable cost, which could delay, prevent or impair our development or potential commercialization efforts.
  • Our existing collaboration arrangements and any that we may enter into in the future may not be successful, which could adversely affect our ability to develop and commercialize our product candidates.
  • Risks Relating to the Ownership of Our Common Stock
  • Future sales of our common stock, or the perception that future sales may occur, may cause the market price of our common stock to decline, even if our business is doing well.
  • Because of the speculative nature of an investment in our company, you may lose your entire investment.
  • Certain of our founding stockholders, plus our existing officers and directors, control a substantial interest in us and thus may influence certain actions requiring stockholder vote.
  • Sales of a significant number of shares of our common stock in the public markets, or the perception that such sales could occur, could depress the market price of our common stock.
  • The requirements of being a public company may strain our resources, divert management’s attention and affect our ability to attract and retain executive management and qualified board members.
  • We are an “emerging growth company” and any decision on our part to comply only with certain reduced reporting and disclosure requirements applicable to emerging growth companies could make shares of our common stock less attractive to investors.
  • We are a “smaller reporting company” and, even if we no longer qualify as an emerging growth company, we may still be subject to reduced reporting requirements.
  • If we fail to maintain compliance with Nasdaq Listing Rules, our shares may be delisted from Nasdaq, which would result in a limited trading market for our shares and make obtaining future debt or equity financing more difficult for the Company.
  • If our shares were to be delisted from Nasdaq, they may become subject to the SEC’s “penny stock” rules.
  • Some provisions of Florida law and our amended and restated articles of incorporation and amended and restated bylaws may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition would be beneficial to our shareholders and may prevent attempts by our shareholders to replace or remove our current management.
  • Our amended and restated bylaws designate the state courts located within the state of Florida as the exclusive forum for substantially all disputes between us and our shareholders and the federal district courts as the exclusive forum for Securities Act claims, which could limit our shareholders’ ability to obtain a favorable judicial forum for disputes with us.
  • Securities or industry analysts may not regularly publish reports on us, which could cause the price of our securities or trading volumes to decline.
  • We will likely conduct further offerings of our equity securities in the future, in which case your proportionate interest may become diluted.
  • We may issue shares of preferred stock in the future, which could make it difficult for another company to acquire us or could otherwise adversely affect holders of our common stock, which could depress the price of our common stock.
  • We have never declared or paid any cash dividends or distributions on our capital stock. We do not anticipate paying any cash dividends on our common stock in the foreseeable future.
  • Risks Related to the planned merger with TELI
  • Because TELI has a limited operating history, you may not be able to accurately evaluate TELI’s operations.
  • TELI is an early development-stage company with no revenues.
  • TELI has significant and increasing liquidity needs and will require additional funding.
  • TELI has yet to generate revenues or achieve a profit and may not generate revenue or achieve a profit for many years, if at all.
  • TELI does not own rights to Telomir-1
  • TELI’s rights to Telomir-1 are subject to royalties.
  • Conflicts of interest may arise between TELI and MIRALOGX.
  • TELI’s product candidates, if approved, may not achieve the expected market acceptance and, consequently, limit TELI’s ability to generate revenue.
  • If the price for any future approved products decreases or if government and other third-party payers do not provide coverage and adequate reimbursement levels, TELI’s revenue and prospects for profitability will suffer.
  • TELI expects to face intense competition, often from companies with greater resources and experience.
  • There are several conflicts of interests inherent in the Merger.
  • Following the Merger, the TELI shareholders may potentially own a majority of TELO.
  • There is no assurance when or if the Merger will be completed.
  • The price of TELO’s common stock is subject to fluctuations
  • The Merger may be time-consuming to complete and may not be completed in a timely manner, or at all, due to pending or potential litigation or regulatory challenges.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
    SEC EDGAROther events
  31. 31
  32. 32
    SEC EDGAROther events
  33. 33
    SEC EDGAROther events
  34. 34
  35. 35
  36. 36
  37. 37